ClinicalTrials.gg
CompletedNCT04772365Updated Nov 29, 2022

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects

A Phase 1 interventional study of SHR-1819 and Placebo in Asthma, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
10th of 15
52 · median 84
Started
2021
with 4 others
Phase 1
7 of 15
1 open now
Registered
2nd of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 10th largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 2nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a single center, randomized, double-blind, placebo-controlled, single and multiple dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous administered SHR-1819 in healthy subjects

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written .
  2. Be able to comply with all the requirements and able to complete the study.
  3. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form.
  4. No abnormalities in medical history, general physical examination, vital signs, and laboratory tests.
  5. Men and women of (WOCBP) must agree to take effective methods and have no plan to have a child from signing the consent form to 16 weeks after IP administration.

Exclusion criteria

Exclusion Criteria:

  1. Positive virus (HBsAg), virus (HCV-Ab), (HIV-Ab), or QuantiFERON-TB Gold tests at screening;
  2. Participation in clinical trials of other drugs or medical devices within 3 months prior to screening (according to the date of signed consent form), or in the follow-up period of a clinical study
  3. Severe injuries or surgeries within 6 months before screening or plan to do surgeries during the trial
  4. Any other circumstances that, in the investigator's judgment, may increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-1819

  • Placebo comparator
    Treatment group B

    Drug: Placebo

Interventions

  • SHR-1819 will be subcutaneously administered with different dose levels;

  • DrugPlacebo

    Placebo will be subcutaneously administered with different dose levels;

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of adverse events

    Time frame: Start of Treatment to end of study(about 13 weeks)

Secondary outcomes

  1. Pharmacokinetics-AUC0-last

    Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration

    Time frame: Start of Treatment to end of study (about 13 weeks)

  2. Pharmacokinetics-AUC0-inf

    Area under the concentration-time curve from time 0 to infinity after SHR-1819 administration

    Time frame: Start of Treatment to end of study (approximately 13 weeks)

  3. Pharmacokinetics-Tmax

    Time to Cmax of SHR-1819

    Time frame: Up to 13 weeks

  4. Pharmacokinetics-Cmax

    Maximum observed concentration of SHR-1819

    Time frame: Up to 13 weeks

  5. Pharmacokinetics-CL/F

    Apparent clearance of SHR-1819

    Time frame: Up to 13 weeks

  6. Pharmacokinetics-Vz/F

    Apparent volume of distribution during terminal phase of SHR-1819

    Time frame: Up to 13 weeks

  7. Pharmacokinetics-t1/2

    Terminal elimination half-life of SHR-1819

    Time frame: Up to 13 weeks

  8. Change from baseline to end of treatment for Thymus and activation-regulated chemokine(TARC/CCL17)

    Thymus and activation-regulated chemokine(TARC/CCL17)

    Time frame: Up to 13 weeks

  9. Change from baseline to end of treatment for IgE

    IgE

    Time frame: Up to 13 weeks

  10. Immunogenicy of SHR-1819 after administration

    Anti-drug antibody

    Time frame: Up to 13 weeks]

  11. Pharmacokinetics-AUCtau for multi-dose

    Area under the concentration-time curve from time 0 to last time point after SHR-1819 administration

    Time frame: Start of Treatment to end of study (about 13 weeks)

  12. Pharmacokinetics- Ctrough for multi-dose

    Minimum observed concentration of SHR-1819

    Time frame: Up to 13 weeks

  13. Pharmacokinetics- Racc for multi-dose

    Accumulation ratio of SHR-1819

    Time frame: Up to 13 weeks

07

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, Changsha 410013, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Dec 2021, 9 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 9 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Feb 26, 2021
StartActual
Mar 1, 2021
Primary completionActual
Dec 10, 2021
CompletionActual
Dec 10, 2021
Last update
Nov 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04772365
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Mar 1, 2021
Primary completion
Dec 10, 2021
Completion
Dec 10, 2021
Last update
Nov 29, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1819

Start the discussion